Adverse effects of microparticles on transfusion of stored red blood cell concentrates
Hematology, Transfusion and Cell Therapy · 2024-11 · 46 · S48-S56
DOI: 10.1016/j.htct.2024.01.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematology, Transfusion and Cell Therapy, 2024-11. Verfasst von Jie Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Blood Transfusion, Shanghai Blood Center, Shanghai, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Shanghai Municipality, Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Background
Systemic and pulmonary coagulopathy and inflammation are important characteristics of transfusion-related acute lung injury (TRALI). Whether microparticles that accumulate in transfused red blood cell concentrates (RBCs) have proinflammatory and procoagulant potential and contribute to adverse reactions of RBC transfusions is unclear.
Aim
To investigate the ability of microparticles in stored RBCs to promote thrombin generation and induce human pulmonary microvascular endothelial cell (HMVEC) activation and damage.
Methods
The number and size of microparticles were determined by flow cytometric and nanoparticle tracking analyses, respectively. Thrombin generation and the intrinsic coagulation pathway were assayed by a calibrated automated thrombogram and by measuring activated partial thromboplastin time (aPTT), respectively. The expression of ICAM-1 and the release of cytokines by endothelial cells were detected by flow cytometric analyses. HMVEC damage was assessed by incubating lipopolysaccharide-activated endothelial cells with MP-primed polymorphonuclear neutrophils (PMNs).
Results
The size of the microparticles in the RBC supernatant was approximately 100-300 nm. Microparticles promoted thrombin generation in a dose-dependent manner and the aPTT was shortened. Depleting microparticles from the supernatant of RBCs stored for 35 days by either filtration or centrifugation significantly decreased the promotion of thrombin generation. The expression of ICAM-1 on HMVECs was increased significantly by incubation with isolated microparticles. Furthermore, microparticles induced the release of interleukin-6 (IL-6) and interleukin-8 (IL-8) from HMVECs. Microparticles induced lipopolysaccharide-activated HMVEC damage by priming PMNs, but this effect was prevented by inhibiting the PMNs respiratory burst with apocynin.
Conclusion
Microparticles in stored RBCs promote thrombin generation, HMVEC activation and damage which may be involved in TRALI development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shanghai Institute of Blood Transfusion, Shanghai Blood Center, Shanghai, China.
- Department of Transfusion Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
- Shanghai Institute of Blood Transfusion, Shanghai Blood Center, Shanghai, China. Electronic address: xierufeng@sbc.org.cn.
Förderung
- Natural Science Foundation of Shanghai Municipality
- Shanghai Municipal Health Commission
Zitieren
APA
Yang, J., Yang, Y., Gao, L., Jiang, X., Sun, J., Wang, Z., & Xie, R. (2024). Adverse effects of microparticles on transfusion of stored red blood cell concentrates. Hematology, Transfusion and Cell Therapy, 46, S48-S56. https://doi.org/10.1016/j.htct.2024.01.007
Vancouver
Yang J, Yang Y, Gao L, Jiang X, Sun J, Wang Z, et al. Adverse effects of microparticles on transfusion of stored red blood cell concentrates. Hematology, Transfusion and Cell Therapy. 2024;46:S48-S56. doi:10.1016/j.htct.2024.01.007
BibTeX
@article{Yang2024,
author = {Yang, Jie and Yang, Yiming and Gao, Li and Jiang, Xueyu and Sun, Juan and Wang, Zhicheng and Xie, Rufeng},
title = {Adverse effects of microparticles on transfusion of stored red blood cell concentrates},
journal = {Hematology, Transfusion and Cell Therapy},
year = {2024},
volume = {46},
pages = {S48--S56},
doi = {10.1016/j.htct.2024.01.007}
}
EUVIMED